Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7624107 | 0.95 | HTT (0.42) | L3MBTL1HTTCCR2ALDH1A1CYP3A4 | |
| SCHEMBL19175556 | 0.89 | ALDH1A1 (0.33) | L3MBTL1HTTCCR2ALDH1A1CYP3A4 | |
| SCHEMBL6738180 | 0.89 | ALDH1A1 (0.33) | L3MBTL1HTTCCR2ALDH1A1CYP3A4 | |
| SCHEMBL23835858 | 0.86 | CCR2 (0.43) | L3MBTL1HTTCCR2HSD17B10ALDH1A1 | |
| SCHEMBL24029012 | 0.83 | CCR2 (0.44) | L3MBTL1HTTCCR2HSD17B10ALDH1A1 | |
| SCHEMBL24449996 | 0.82 | CCR2 (0.49) | L3MBTL1CCR2HSD17B10ALDH1A1 | |
| SCHEMBL23835732 | 0.80 | CCR2 (0.51) | L3MBTL1CCR2ALDH1A1 | |
| SCHEMBL6734281 | 0.80 | L3MBTL1 (0.43) | L3MBTL1HTTCCR2ALDH1A1KDM4E | |
| SCHEMBL10160076 | 0.80 | L3MBTL1 (0.43) | L3MBTL1HTTCCR2ALDH1A1KDM4E | |
| SCHEMBL12210573 | 0.80 | L3MBTL1 (0.43) | L3MBTL1HTTCCR2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2020068600-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-6680331-B2 | ADMINISTERING DIETHYL LACTAMS SUCH AS 3,3-DIETHYL-2-PYRROLIDINONE FOR INDUCING ANESTHESIA OR CONSCIOUS SEDATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-01-20 | — | — | US | disclosed |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-04-24 | — | — | US | disclosed |
| WO-2003007940-A1 | LACTAM AND THIOLACTAM DERIVATIVES AS ANESTHETIC AND CONSCIOUS SEDATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-01-30 | — | — | WO | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | L3MBTL1 605/4885HTT 2625/4885CCR2 1005/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | L3MBTL1 223/4885HTT 1484/4885CCR2 1295/4885 |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | GABRD, GABRE, CCT8 | L3MBTL1 1118/4885HTT 3273/4885CCR2 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.